Polycystic Ovary Syndrome, commonly known as PCOS, has officially been renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS, following an international consensus initiative involving more than 50 medical organizations, researchers, clinicians, and patient advocacy groups.
The recommendation was published in The Lancet in May 2026 after years of debate among experts who argued the decades-old term no longer reflected the science behind the condition.
Organizations involved in the initiative included the Endocrine Society and the International PCOS Network. Researchers said the previous terminology placed disproportionate focus on ovarian cysts and fertility while failing to capture the disorder’s broader endocrine and metabolic impact.
“PCOS” has long been associated with irregular periods, infertility, and cysts on the ovaries. But experts now describe the condition as a multisystem disorder frequently linked to insulin resistance, chronic inflammation, elevated androgen hormones, metabolic syndrome, type 2 diabetes risk, and long-term cardiovascular complications.
The condition affects an estimated 1 in 8 women globally, according to experts involved in the initiative, though many patients remain undiagnosed for years.
Why Experts Renamed PCOS to PMOS
One of the primary criticisms of the term “Polycystic Ovary Syndrome” was that many women diagnosed with the condition never actually had ovarian cysts.
Professor Helena Teede, one of the leaders involved in the international consensus process, said the goal was to adopt terminology that more accurately reflected the condition’s full-body impact.
Researchers involved in the initiative said the older terminology had become scientifically outdated and may have contributed to delayed diagnosis, fragmented care, and misunderstanding surrounding the disorder.
The updated name, Polyendocrine Metabolic Ovarian Syndrome, emphasizes that multiple hormone systems and metabolic pathways may be involved.
Experts say the condition is increasingly understood through a broader endocrine and metabolic framework involving:
- insulin resistance
- androgen excess
- ovulatory dysfunction
- inflammation
- metabolic abnormalities
- and elevated cardiovascular risk
Why Diagnosis Has Historically Been Difficult
Experts say one of the biggest challenges surrounding PMOS is that there is no single definitive test used to diagnose it.
Instead, diagnosis is typically based on a combination of symptom history, hormone testing, metabolic evaluation, physical exam findings, and sometimes ultrasound imaging.
Historically, many women entered the healthcare system through symptoms that appeared unrelated.
A patient may have sought care for irregular menstrual cycles through gynecology, acne through dermatology, elevated blood sugar through primary care, infertility through reproductive medicine, or insulin resistance through endocrinology.
Each symptom may have been treated appropriately on its own.
But over time, researchers say evidence increasingly showed many of those clinical findings were interconnected manifestations of the same endocrine and metabolic disorder.
That evolving understanding is one of the central reasons experts pushed for the change in terminology.
What Researchers Now Understand About the Condition
Although the exact cause remains complex and multifactorial, researchers say insulin resistance appears to play a major role in many patients.
Elevated insulin levels can contribute to increased androgen production, disrupted ovulation, inflammation, and worsening metabolic dysfunction.
That may help explain why many women with PMOS experience symptoms extending beyond fertility concerns, including:
- irregular or absent periods
- acne
- facial or body hair growth
- scalp hair thinning
- unexplained weight gain
- difficulty losing weight
- fatigue
- elevated cholesterol
- and prediabetes or diabetes risk
Some women may also develop acanthosis nigricans, a darkened, velvety skin appearance commonly seen around the neck, underarms, groin, beneath the breasts, or in other skin folds. Experts say this can be an important visible sign of insulin resistance.
What the PCOS to PMOS Change Means for Patients
Experts say the name change does not create a new disease. Instead, they say it reflects a broader shift in how the condition is evaluated and understood.
Researchers involved in the initiative hope the updated terminology encourages:
- earlier recognition
- broader metabolic screening
- more comprehensive endocrine evaluation
- and more coordinated care across specialties
Implementation of the updated terminology is expected to continue over the coming years as healthcare systems, medical organizations, and educational institutions transition toward PMOS.
For many women, experts say the change represents more than updated terminology.
It reflects growing recognition that symptoms once treated as isolated concerns may have been connected all along.
